Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Xenetic Biosciences, Inc. (XBIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6950-0.1050 (-5.83%)
At close: 4:00PM EDT
1.6999 +0.00 (+0.29%)
After hours: 07:19PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.8000
Open1.7900
Bid1.6800 x 800
Ask1.7100 x 900
Day's Range1.6638 - 1.7900
52 Week Range0.7600 - 5.8500
Volume388,700
Avg. Volume9,976,618
Market Cap22.689M
Beta (5Y Monthly)2.60
PE Ratio (TTM)N/A
EPS (TTM)-1.4690
Earnings DateAug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for XBIO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Xenetic Biosciences, Inc.
    NKTR: Raising target price to $14.00NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $14.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    9 days agoArgus Research
View more
  • ACCESSWIRE

    Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent

    Allowance bolsters intellectual property portfolio for differentiated personalized CAR T platform technology, XCARTFRAMINGHAM, MA / ACCESSWIRE / September 9, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced the United States Patent and Trademark Office (USPTO) has issued Xenetic a Notice of Allo

  • ACCESSWIRE

    Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    FRAMINGHAM, MA / ACCESSWIRE / September 8, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced that Jeffrey F.

  • ACCESSWIRE

    Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

    * Continued execution on XCART TM pre-clinical development plan and progress toward IND-enabling studies * Strong royalty growth with PolyXen® platform technology * Bolstered cash position with recently completed $12.5 million private placementFRAMINGHAM, MA / ACCESSWIRE / August 13, 2021 / Xenetic Biosciences, Inc.

Advertisement
Advertisement